Cyclooxygenase-2 inhibitors in colorectal cancer prevention: point

Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology
Nadir Arber

Abstract

The limited success of current treatments for most advanced common malignancies highlights the importance of cancer prevention. Clinical trials on cyclooxygenase (COX) inhibitor drugs showed the potential of chemoprevention as a strategy for reducing cancer incidence, although not without associated side effects. The attractiveness of these drugs partly stems from an ability to engage multiple mechanisms of action by their potential to influence multiple components of the carcinogenesis pathway, from initiation to progression. There are two isoforms of the COX enzymes. COX-1 is constitutively expressed in normal tissues and serves as a "housekeeper" of mucosal integrity, whereas COX-2 is an immediate early response gene that is highly inducible by neoplastic and inflammatory stimuli. COX-2 is significantly overexpressed in colorectal neoplasms, making it an attractive therapeutic target. The drug market has been revolutionized by the development of preparations targeted selectively against COX-2, and a proof of concept has been achieved. Chemoprevention of colorectal cancer is already possible with celecoxib, but it is still not the ultimate drug of choice especially because of the cardiovascular risk associated with COX-2 inhi...Continue Reading

References

Jun 25, 1974·Prostaglandins·B M Jaffe
Apr 1, 1996·Gastroenterology·R N DuBoisA J Entingh
Jul 9, 1999·The Journal of Pathology·X HaoI C Talbot
Jun 30, 2000·The New England Journal of Medicine·G SteinbachG Kelloff
Aug 11, 2001·The New England Journal of Medicine·G A FitzGerald, C Patrono
May 30, 2003·International Journal of Colorectal Disease·J K GroverY K Joshi
Jun 18, 2003·Proceedings of the National Academy of Sciences of the United States of America·Maria Elena MartinezEugene W Gerner
Nov 25, 2003·Digestive Diseases and Sciences·A HallakN Arber
Feb 18, 2004·Current Cancer Drug Targets·Chinthalapally V Rao, Bandaru S Reddy
Oct 28, 2004·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·A PilottoG Leandro
Feb 17, 2005·The New England Journal of Medicine·Robert S BresalierUNKNOWN Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators
Feb 17, 2005·The New England Journal of Medicine·Scott D SolomonUNKNOWN Adenoma Prevention with Celecoxib (APC) Study Investigators
Feb 17, 2005·The New England Journal of Medicine·Nancy A NussmeierKenneth M Verburg
Jul 21, 2005·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Mairi MacarthurEmad M El-Omar
Jan 6, 2006·The Journal of Clinical Investigation·Tilo GrosserGarret A FitzGerald
Feb 24, 2006·Nature Reviews. Cancer·Cornelia M UlrichJohn D Potter
May 12, 2006·Molecular Carcinogenesis·Frank A Sinicrope
Sep 1, 2006·The New England Journal of Medicine·Monica M BertagnolliUNKNOWN APC Study Investigators
Sep 1, 2006·The New England Journal of Medicine·Nadir ArberUNKNOWN PreSAP Trial Investigators
Sep 14, 2006·JAMA : the Journal of the American Medical Association·David J Graham
Nov 8, 2006·Gastroenterology·John A BaronUNKNOWN APPROVe Trial Investigators
Nov 30, 2006·Current Opinion in Gastroenterology·Robert S Bresalier
May 25, 2007·The New England Journal of Medicine·Andrew T ChanCharles S Fuchs
Apr 9, 2008·Gastroenterology·Nadir Arber, Bernard Levin

❮ Previous
Next ❯

Citations

Aug 13, 2009·JAMA : the Journal of the American Medical Association·Andrew T ChanCharles S Fuchs
Mar 27, 2010·International Journal of Cell Biology·Cyril SobolewskiMarc Diederich
Mar 5, 2010·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Yoshifumi BabaShuji Ogino
Apr 1, 2010·Molecular Cancer Research : MCR·Jae Il KimYehia Daaka
Jul 2, 2011·International Journal of Nanomedicine·Naveen K ThakralDipak K Majumdar
Feb 9, 2012·Expert Opinion on Therapeutic Targets·Doran AviviNadir Arber
Aug 14, 2009·Expert Review of Gastroenterology & Hepatology·Patricia A Thompson, Eugene W Gerner
Nov 15, 2011·Journal of Comparative Pathology·Justina PradaIsabel Pires
Sep 24, 2011·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Reza Entezari HeraviJavad Behravan
Mar 9, 2010·Journal of Comparative Pathology·I PiresF L Queiroga
Sep 25, 2009·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Sarah Kraus, Nadir Arber
Jun 1, 2012·TheScientificWorldJournal·A Manzano, P Pérez-Segura
Apr 16, 2009·Pharmacoepidemiology and Drug Safety·Jessica ChubakMargaret T Mandelson
Jun 4, 2013·Asian Pacific Journal of Cancer Prevention : APJCP·Yu-Jie WangYing-Jie Ma
Jul 11, 2009·Current Opinion in Pharmacology·Sarah Kraus, Nadir Arber
Aug 26, 2014·Clinics and Research in Hepatology and Gastroenterology·Lin Zhang, Xiao-Ming Fan
Nov 5, 2016·Clinical Colorectal Cancer·Yongsong LiuYingting Zhu
Jun 19, 2009·Toxicologic Pathology·Eliahu GolombHerzl Schwalb
Sep 3, 2010·The American Journal of Gastroenterology·Christine Cole JohnsonUNKNOWN PLCO Trial Team
Feb 1, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anne-Sophie HamyFabien Reyal
May 2, 2017·Frontiers in Oncology·Jeff KamtaSihem Ait-Oudhia
Jun 11, 2019·Expert Review of Clinical Pharmacology·Zhongguang Chen, Lili Jiang
Jul 8, 2011·Cancer Prevention Research·Chan Young OckMyung-Hee Chung
Feb 4, 2021·Bioengineering & Translational Medicine·Daniel C PanSamir Mitragotri
Mar 24, 2021·International Journal of Cancer. Journal International Du Cancer·Rajitha IndukuriCecilia Williams
Apr 17, 2021·Frontiers in Endocrinology·Rajitha IndukuriCecilia Williams
Aug 20, 2021·Expert Opinion on Therapeutic Targets·Esmat AbdiMohammad Hassan Esmailnejad

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.